Source: Seattle Times
‘Novo Nordisk A/S and Eli Lilly & Co. must add warning labels to their weight-loss and diabetes drugs about a potential rare side effect that could permanently damage patients’ vision. The U.S. Food and Drug Administration will now require GLP-1 drugs including Novo’s Wegovy and Ozempic and Lilly’s Mounjaro, Zepbound and Foundayo to carry warnings that they may increase the risk of non-arteritic anterior ischemic optic neuropathy, or NAION. The rare condition can cause decreased vision and potentially permanent vision loss.” (11/09/26)